Page last updated: 2024-12-07
cgp 36742
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
(3-aminopropyl)(n-butyl)phosphinic acid: interacts preferably with GABA-B RECEPTORS (IC50=38 μM) and GABA-C receptors (IC50=62 μM) over GABA-A RECEPTORS (IC50=508 μM) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 130021 |
| CHEMBL ID | 112797 |
| SCHEMBL ID | 195133 |
| MeSH ID | M0211953 |
Synonyms (40)
| Synonym |
|---|
| bdbm50032982 |
| cgp36742 |
| 3-aminopropyl(butyl)phosphinic acid |
| (3-amino-propyl)-butyl-phosphinic acid |
| gtpl1085 |
| 3-aminopropyl-butylphosphinic acid |
| dvd-742 |
| sgs-742 |
| cgp-36742 |
| lu-ae-58479 |
| PDSP1_001479 |
| PDSP2_001463 |
| cgp 36742 |
| sgs 742 |
| phosphinic acid, (3-aminopropyl)butyl- |
| (3-aminopropyl)butylphosphinic acid |
| (3-aminopropyl)(n-butyl)phosphinic acid |
| L000169 |
| sgs742 |
| CHEMBL112797 , |
| 145537-81-1 |
| unii-gbz5uc0rme |
| 123690-78-8 |
| gbz5uc0rme , |
| 3-aminopropyl(butyl)-phosphinic acid |
| 3-aminopropyl(n-butyl)phosphinic acid |
| ONNMDRQRSGKZCN-UHFFFAOYSA-N |
| 3-aminopropyl(n-butyl) phosphinic acid |
| SCHEMBL195133 |
| 3-aminopropyl-butyl phosphinic acid |
| DTXSID10154063 |
| phosphinic acid,(3-aminopropyl)butyl- |
| cgp36742, >=97% (nmr) |
| DB05010 |
| HY-121599 |
| Q27075900 |
| CS-0082820 |
| phosphinic acid, p-(3-aminopropyl)-p-butyl- |
| YEA69078 |
| AKOS040741539 |
Research Excerpts
Overview
CGP 36742 is a weak GABA(B) receptor antagonist.
| Excerpt | Reference | Relevance |
|---|---|---|
| "CGP 36742 is a weak GABA(B) receptor antagonist. " | ( Potentiation of NMDA receptor function through somatostatin release: a possible mechanism for the cognition-enhancing activity of GABA(B) receptor antagonists. Feligioni, M; Gemignani, A; Ghersi, C; Pittaluga, A; Raiteri, M, 2001) | 1.75 |
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " Pharmacokinetic results after a single oral (600 mg) dose included maximum observed concentration (Cmax), 27 mumol/L (95% CI 22." | ( Pharmacokinetics of CGP 36,742, an orally active GABAB antagonist, in humans. Farger, G; Gleiter, CH; Möbius, HJ, 1996) | 0.29 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " SGS742 was well tolerated in experimental animals as well as in young and elderly human volunteers with an absolute bioavailability in humans of 44%." | ( SGS742: the first GABA(B) receptor antagonist in clinical trials. Froestl, W; Gallagher, M; Jenkins, H; Madrid, A; Melcher, T; Mondadori, CG; Pearlman, R; Teichman, S, 2004) | 0.32 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " GBL dosing was initiated at 100 mg/kg/day and then progressively increased stepwise by increments of 100 mg/kg to a final dose of 600 mg/kg." | ( Chronic intragastric administration of gamma-butyrolactone produces physical dependence in baboons. Brown, PR; Froestl, W; Gibson, KM; Goodwin, AK; Griffiths, RR; Jakobs, C; Weerts, EM, 2006) | 0.33 |
| " Signs of physical dependence were also demonstrated when chronic GBL dosing was discontinued." | ( Chronic intragastric administration of gamma-butyrolactone produces physical dependence in baboons. Brown, PR; Froestl, W; Gibson, KM; Goodwin, AK; Griffiths, RR; Jakobs, C; Weerts, EM, 2006) | 0.33 |
| "These data indicate that, like GHB, chronic GBL dosing produced physical dependence that likely involved the GABA-B receptor." | ( Chronic intragastric administration of gamma-butyrolactone produces physical dependence in baboons. Brown, PR; Froestl, W; Gibson, KM; Goodwin, AK; Griffiths, RR; Jakobs, C; Weerts, EM, 2006) | 0.33 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (21)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Gamma-aminobutyric acid receptor subunit pi | Homo sapiens (human) | IC50 (µMol) | 508.0000 | 0.0001 | 1.0201 | 6.0000 | AID72320 |
| Gamma-aminobutyric acid receptor subunit delta | Homo sapiens (human) | IC50 (µMol) | 508.0000 | 0.0001 | 1.0201 | 6.0000 | AID72320 |
| Gamma-aminobutyric acid type B receptor subunit 2 | Homo sapiens (human) | IC50 (µMol) | 38.0000 | 0.0500 | 0.3300 | 0.6100 | AID569885 |
| Gamma-aminobutyric acid type B receptor subunit 2 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 38.0000 | 0.0000 | 1.0101 | 6.8100 | AID71394 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Homo sapiens (human) | IC50 (µMol) | 508.0000 | 0.0001 | 1.1494 | 8.0000 | AID569889; AID72320 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Homo sapiens (human) | IC50 (µMol) | 508.0000 | 0.0001 | 1.0393 | 6.0000 | AID72320 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Homo sapiens (human) | IC50 (µMol) | 508.0000 | 0.0001 | 1.2915 | 8.0000 | AID569889; AID72320 |
| Gamma-aminobutyric acid receptor subunit rho-1 | Homo sapiens (human) | IC50 (µMol) | 62.0000 | 2.2200 | 2.2200 | 2.2200 | AID406571; AID569661 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Homo sapiens (human) | IC50 (µMol) | 508.0000 | 0.0001 | 1.3018 | 8.0000 | AID72320 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Homo sapiens (human) | IC50 (µMol) | 508.0000 | 0.0001 | 0.9800 | 6.0000 | AID72320 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Homo sapiens (human) | IC50 (µMol) | 508.0000 | 0.0001 | 1.1993 | 6.0000 | AID72320 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Homo sapiens (human) | IC50 (µMol) | 508.0000 | 0.0001 | 1.0201 | 6.0000 | AID72320 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Homo sapiens (human) | IC50 (µMol) | 508.0000 | 0.0001 | 0.9374 | 6.0000 | AID569889; AID72320 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Homo sapiens (human) | IC50 (µMol) | 508.0000 | 0.0001 | 1.0193 | 6.0000 | AID72320 |
| Gamma-aminobutyric acid receptor subunit epsilon | Homo sapiens (human) | IC50 (µMol) | 508.0000 | 0.0001 | 1.0201 | 6.0000 | AID72320 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Homo sapiens (human) | IC50 (µMol) | 508.0000 | 0.0001 | 1.0201 | 6.0000 | AID72320 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Homo sapiens (human) | IC50 (µMol) | 508.0000 | 0.0001 | 1.0201 | 6.0000 | AID72320 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Homo sapiens (human) | IC50 (µMol) | 508.0000 | 0.0001 | 1.0201 | 6.0000 | AID72320 |
| Gamma-aminobutyric acid type B receptor subunit 1 | Homo sapiens (human) | IC50 (µMol) | 38.0000 | 0.0500 | 0.3300 | 0.6100 | AID569885 |
| Gamma-aminobutyric acid receptor subunit theta | Homo sapiens (human) | IC50 (µMol) | 508.0000 | 0.0001 | 1.0201 | 6.0000 | AID72320 |
| Gamma-aminobutyric acid type B receptor subunit 1 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 38.0000 | 0.0000 | 1.0532 | 6.8100 | AID71394 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (41)
Molecular Functions (22)
Ceullar Components (42)
Bioassays (25)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID30476 | Inhibition of [3H]N-6-CA binding to Adenosine A1 receptor of central nervous system | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17 | Phosphinic acid analogues of GABA. 2. Selective, orally active GABAB antagonists. |
| AID6362 | Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17 | Phosphinic acid analogues of GABA. 2. Selective, orally active GABAB antagonists. |
| AID142910 | Inhibition of [3H]CMD binding to muscarinic Ach receptor of central nervous system | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17 | Phosphinic acid analogues of GABA. 2. Selective, orally active GABAB antagonists. |
| AID88627 | Inhibition of [3H]tiotidine binding to histamine 2 receptor of central nervous system | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17 | Phosphinic acid analogues of GABA. 2. Selective, orally active GABAB antagonists. |
| AID163312 | Inhibition of [3H]-AMPA binding to Quisqualate receptor of central nervous system | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17 | Phosphinic acid analogues of GABA. 2. Selective, orally active GABAB antagonists. |
| AID143460 | Inhibition of [3H]L-glutamate binding to NMDA receptor of central nervous system | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17 | Phosphinic acid analogues of GABA. 2. Selective, orally active GABAB antagonists. |
| AID3454 | Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17 | Phosphinic acid analogues of GABA. 2. Selective, orally active GABAB antagonists. |
| AID152091 | Inhibition of [3H]naloxone binding to mu-opiate receptor of central nervous system | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17 | Phosphinic acid analogues of GABA. 2. Selective, orally active GABAB antagonists. |
| AID35779 | Inhibition of [3H]clonidine binding to Alpha-2 adrenergic receptor of central nervous system. | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17 | Phosphinic acid analogues of GABA. 2. Selective, orally active GABAB antagonists. |
| AID40990 | Inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of central nervous system | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17 | Phosphinic acid analogues of GABA. 2. Selective, orally active GABAB antagonists. |
| AID142911 | Inhibition of [3H]-QNB binding to muscarinic receptor of central nervous system | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17 | Phosphinic acid analogues of GABA. 2. Selective, orally active GABAB antagonists. |
| AID569889 | Antagonist activity at human recombinant GABAA alpha1beta2gamma2L receptor expressed in Xenopus laevis oocytes assessed as inhibition of GABA-induced current by two electrode voltage clamp technique | 2011 | ACS medicinal chemistry letters, Jan-13, Volume: 2, Issue:1 | Novel Cyclic Phosphinic Acids as GABAC ρ Receptor Antagonists: Design, Synthesis, and Pharmacology. |
| AID87689 | Inhibition of [3H]doxepine binding to histamine-1 receptor of central nervous system. | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17 | Phosphinic acid analogues of GABA. 2. Selective, orally active GABAB antagonists. |
| AID5133 | Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17 | Phosphinic acid analogues of GABA. 2. Selective, orally active GABAB antagonists. |
| AID72320 | Inhibition of [3H]muscimol binding to Gamma-aminobutyric acid A (GABA-A) receptor of the central nervous system. | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17 | Phosphinic acid analogues of GABA. 2. Selective, orally active GABAB antagonists. |
| AID91467 | Inhibition of [3H]kainate binding to Ionotropic glutamate receptor kainate of central nervous system | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17 | Phosphinic acid analogues of GABA. 2. Selective, orally active GABAB antagonists. |
| AID569885 | Antagonist activity at human recombinant GABAb 1b/2 receptor expressed in Xenopus laevis oocytes co-expressing GIRK1/4 assessed as inhibition of GABA-induced current by two electrode voltage clamp technique | 2011 | ACS medicinal chemistry letters, Jan-13, Volume: 2, Issue:1 | Novel Cyclic Phosphinic Acids as GABAC ρ Receptor Antagonists: Design, Synthesis, and Pharmacology. |
| AID41899 | Inhibition of [3H]- DHA binding to Beta adrenergic receptor | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17 | Phosphinic acid analogues of GABA. 2. Selective, orally active GABAB antagonists. |
| AID406571 | Antagonist activity at human GABAc Rho1 receptor expressed in Xenopus oocytes assessed as whole cell current production by two electrode voltage clamp method | 2008 | Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13 | Novel gamma-aminobutyric acid rho1 receptor antagonists; synthesis, pharmacological activity and structure-activity relationships. |
| AID569661 | Antagonist activity at human recombinant GABAc rho-1 receptor expressed in Xenopus laevis oocytes assessed as inhibition of GABA-induced current by two electrode voltage clamp technique | 2011 | ACS medicinal chemistry letters, Jan-13, Volume: 2, Issue:1 | Novel Cyclic Phosphinic Acids as GABAC ρ Receptor Antagonists: Design, Synthesis, and Pharmacology. |
| AID71394 | Inhibition of binding of [3H]CGP-27492 to gamma-aminobutyric acid type B receptor of rat cortex. | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17 | Phosphinic acid analogues of GABA. 2. Selective, orally active GABAB antagonists. |
| AID36318 | Inhibition of [3H]prazosin binding to Alpha-1 adrenergic receptor of central nervous system. | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17 | Phosphinic acid analogues of GABA. 2. Selective, orally active GABAB antagonists. |
| AID143776 | Inhibition of [3H]DCKA binding to N-methyl-D-aspartate glutamate receptor 1 of central nervous system | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17 | Phosphinic acid analogues of GABA. 2. Selective, orally active GABAB antagonists. |
| AID175287 | The compound was tested for enhancement of electrically induced release of [3H]GABA from rat cortical slices. | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17 | Phosphinic acid analogues of GABA. 2. Selective, orally active GABAB antagonists. |
| AID211503 | Inhibition of binding to Tachykinin receptor 1 of central nervous system | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17 | Phosphinic acid analogues of GABA. 2. Selective, orally active GABAB antagonists. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (61)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 32 (52.46) | 18.2507 |
| 2000's | 27 (44.26) | 29.6817 |
| 2010's | 1 (1.64) | 24.3611 |
| 2020's | 1 (1.64) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 3 (4.76%) | 5.53% |
| Reviews | 3 (4.76%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 57 (90.48%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||